This article is more than 5 years old. Information may no longer be current.

ThromboGenics reports net loss in 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ThromboGenics reported a net loss of €51.1 million in 2014, compared with a net profit of €26.4 million in 2013, according to a press release.

In addition, ThromboGenics reported decreases in total revenues, gross profit, and cash and investments in fiscal year 2014.

Total revenues were €13.8 million in 2014, a decrease from €112.8 million in 2013, which included €90 million in milestone payments from Alcon.

Gross profit was €9.2 million, a decrease from €106.4 million in the previous year.

Cash and investments were €127.1 million in 2014, a decrease from €172.4 million in 2013.

Sales of Jetrea (ocriplasmin) in the U.S. totaled €8.8 million, a decrease from €20.2 million in 2013. The reduction was a result of decreasing adoption rates of Jetrea for the treatment of vitreomacular adhesion.

ThromboGenics is currently conducting studies to address challenges and determine the optimal use of Jetrea. The company is also beginning to investigate Jetrea for the treatment of diabetic retinopathy.